Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

44.80 -0.75 (-1.65%)
Streaming Delayed Price Updated: 12:58 PM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Supernus Announces First Quarter 2023 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 9, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
News headline image
Supernus Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
FDA Rejects Supernus Pharma's Minimally Invasive Parkinson's Therapy ↗
 
Via Benzinga
News headline image
FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients ↗
 
Via Benzinga
News headline image
Something Happened In Biotech Last Week ↗
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
News headline image
Supernus to Present at the Bank of America 2023 Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Repayment of Convertible Notes
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Participate in Two Upcoming Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Present at the Cowen 43rd Annual Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Enters Into $150 Million Credit Facility
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 28, 2023 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
News headline image
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
News headline image
Supernus to Present at Two November Healthcare Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Third Quarter 2022 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Provides Regulatory Update on SPN-830
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Top Medical Specialties Stocks: Trading Opportunities For Next Week - Sunday, Oct. 2 ↗
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Here is a closer look at some medical stock opportunities... 
Via Talk Markets
News headline image
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
News headline image
Stocks That Made New Highs On Friday, Aug. 19 ↗
On Friday, in spite of the stock market being down, there were several stocks that actually made new highs. 
Via Talk Markets
News headline image
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates ↗
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
News headline image
Looking Into Supernus Pharmaceuticals's Return On Invested Capital ↗
According to Benzinga Pro data Supernus Pharmaceuticals (NASDAQ:SUPN) posted a 88.67% decrease in earnings from Q3. Sales, however, increased by 7.13% over the previous quarter to $159.05 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.